Han et al. reported that thiazolidinediones exhibited an effect on reducing the progression of renal complications in mouse models of obesity and T2DM, especially in combination with SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.